CI
PGNX

Cowen Inc’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Cowen Inc’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18,704
Closed -$140K – 473
2015
Q2 		$140K Hold
18,704
– – 0.01% 399
2015
Q1 		$112K Buy
+18,704
New +$118K 0.01% 366

Other funds holding PGNX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cowen Inc's PGNX Position: Q3 2015 in Review

Cowen Inc sold out of Progenics Pharmaceuticals Inc (PGNX) in Q3 2015, closing a stake of 18,704 shares — an estimated $140K sold.

Cowen Inc first reported a position in PGNX in Q1 2015 and held it in 2 quarters. The position peaked at $140K in Q2 2015. 133 funds tracked by Wall St. Rank hold PGNX as of Q3 2015.

  • Cowen Inc reported no remaining Progenics Pharmaceuticals Inc position as of Q3 2015 after selling out during the quarter.
  • Cowen Inc sold 18,704 Progenics Pharmaceuticals Inc shares in Q3 2015, an estimated $140K.
  • Cowen Inc first reported a position in Progenics Pharmaceuticals Inc in Q1 2015 and held it in 2 quarters.
  • Cowen Inc's Progenics Pharmaceuticals Inc position peaked at $140K in Q2 2015.
  • 133 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q3 2015.

Based on Cowen Inc's 13F filing for Q3 2015, filed 13 Nov 2015.